OC
NAGE

Oppenheimer & Co’s Niagen Bioscience NAGE Stock Holding History

Oppenheimer & Co’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,900
Closed -$89.7K – 1690
2024
Q4 		$89.7K Hold
16,900
– – ﹤0.01% 1509
2024
Q3 		$61.7K Hold
16,900
– – ﹤0.01% 1477
2024
Q2 		$46.1K Sell
16,900
-2,700
-14% -$9.03K ﹤0.01% 1409
2024
Q1 		$68.2K Sell
19,600
-8,000
-29% -$14.8K ﹤0.01% 1403
2023
Q4 		$39.5K Hold
27,600
– – ﹤0.01% 1358
2023
Q3 		$40.3K Hold
27,600
– – ﹤0.01% 1349
2023
Q2 		$43.3K Hold
27,600
– – ﹤0.01% 1388
2023
Q1 		$42.2K Sell
27,600
-2,500
-8% -$4.45K ﹤0.01% 1349
2022
Q4 		$50.6K Sell
30,100
-100
-0.3% -$159 ﹤0.01% 1314
2022
Q3 		$37K Sell
30,200
-8,910
-23% -$14.3K ﹤0.01% 1333
2022
Q2 		$65K Buy
39,110
+21,900
+127% +$42.8K ﹤0.01% 1356
2022
Q1 		$42K Sell
17,210
-7,900
-31% -$21.6K ﹤0.01% 1444
2021
Q4 		$94K Buy
25,110
+2,900
+13% +$15.7K ﹤0.01% 1448
2021
Q3 		$139K Hold
22,210
– – ﹤0.01% 1432
2021
Q2 		$219K Buy
22,210
+2,600
+13% +$22.7K ﹤0.01% 1387
2021
Q1 		$183K Sell
19,610
-3,900
-17% -$30.9K ﹤0.01% 1360
2020
Q4 		$113K Buy
+23,510
New +$115K ﹤0.01% 1305
2019
Q1 		– Sell
-50,000
Closed -$172K – 1397
2018
Q4 		$172K Sell
50,000
-42,500
-46% -$148K 0.01% 1127
2018
Q3 		$397K Hold
92,500
– – 0.01% 951
2018
Q2 		$343K Hold
92,500
– – 0.01% 1006
2018
Q1 		$389K Buy
92,500
+50,000
+118% +$262K 0.01% 948
2017
Q4 		$250K Buy
+42,500
New +$230K 0.01% 1130

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oppenheimer & Co's NAGE Position: Q1 2025 in Review

Oppenheimer & Co sold out of Niagen Bioscience (NAGE) in Q1 2025, closing a stake of 16,900 shares — an estimated $89.7K sold.

Oppenheimer & Co first reported a position in NAGE in Q4 2017 and held it in 22 quarters. The position peaked at $397K in Q3 2018. 139 funds tracked by Wall St. Rank hold NAGE as of Q1 2025.

  • Oppenheimer & Co reported no remaining Niagen Bioscience position as of Q1 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 16,900 Niagen Bioscience shares in Q1 2025, an estimated $89.7K.
  • Oppenheimer & Co first reported a position in Niagen Bioscience in Q4 2017 and held it in 22 quarters.
  • Oppenheimer & Co's Niagen Bioscience position peaked at $397K in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2025.

Based on Oppenheimer & Co's 13F filing for Q1 2025, filed 23 Apr 2025.